Drug Search Results
More Filters [+]

Canakinumab

Alternative Names: canakinumab, acz885, ilaris
Latest Update: 2024-09-26
Latest Update Note: Clinical Trial Update

Product Description

Canakinumab (ACZ885, Ilaris) is a human anti-IL-1beta monoclonal antibody developed by Novartis. its mode of action is based on the neutralization of 1beta signaling, resulting in suppression of inflammation in patients with disorders of autoimmune origin. (Sourced from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2828573/)

Mechanisms of Action: IL1 Inhibitor

Novel Mechanism: No

Modality: Antibody

Route of Administration: Subcutaneous

FDA Designation: None *

Approval Status: Approved

Approved Countries: Argentina | Australia | Austria | Belgium | Brazil | Canada | Chile | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | Ireland | Israel | Italy | Japan | Korea | Latvia | Lithuania | Luxembourg | Netherlands | New Zealand | Norway | Peru | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sweden | Switzerland | Taiwan | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Venezuela

Approved Indications: None

Known Adverse Events: None

Company: Novartis
Company Location: BASEL V8 CH 4056
Company CEO: Vasant Narasimhan
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Canakinumab

Countries in Clinic: Argentina, Australia, Austria, Brazil, Canada, Chile, China, Colombia, Czech Republic, Denmark, Finland, France, Germany, Greece, Hong Kong, Hungary, Iceland, India, Italy, Japan, Korea, Lebanon, Malaysia, Netherlands, Norway, Philippines, Poland, Portugal, Romania, Russia, Singapore, Slovakia, Spain, Sweden, Switzerland, Taiwan, Thailand, Turkey, United Kingdom, United States, Unknown Location, Vietnam

Active Clinical Trial Count: 29

Highest Development Phases

Phase 3: Adenocarcinoma|Arthritis|Arthritis, Juvenile|COVID-19|Cold Urticaria|Cryopyrin-Associated Periodic Syndromes|Familial Mediterranean Fever|Lung Cancer|Mevalonate Kinase Deficiency|Non-Small-Cell Lung Cancer|Pancreatic Cancer|Pyoderma Gangrenosum|Still's Disease, Adult-Onset

Phase 2: Acute Monocytic Leukemia|Acute Myelomonocytic Leukemia|Alzheimer Disease|Chronic Myelomonocytic Leukemia|Hepatitis A|Hepatitis, Alcoholic|Juvenile Myelomonocytic Leukemia,|Myelodysplastic Syndrome|Osteoarthritis|Preleukemia

Phase 1: Healthy Volunteers|Pancreatic Ductal Carcinoma|Renal Cell Carcinoma

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

CANAL

P3

Active, not recruiting

Lung Cancer

2034-03-14

PanCAN_Precision Promise

P3

Active, not recruiting

Adenocarcinoma|Pancreatic Cancer

2027-06-24

CACZ885U2301

P3

Recruiting

Non-Small-Cell Lung Cancer

2027-06-07

NCI-2019-08494

P2

Recruiting

Juvenile Myelomonocytic Leukemia,|Chronic Myelomonocytic Leukemia|Acute Monocytic Leukemia|Myelodysplastic Syndrome|Preleukemia|Acute Myelomonocytic Leukemia

2026-12-31

Recent News Events